Vol.

No.

June 10, 2022Jun 10, 2022

DOWNLOAD THE PDF

ASCO’s “rock concert” moments came 17 years apart—in 2005 and 2022 DESTINY-04 results extend HER2-targeted therapy to a larger population in breast cancer

Cover Story

Guest Editorial

ASCO’s “rock concert” moments came 17 years apart—in 2005 and 2022

DESTINY-04 results extend HER2-targeted therapy to a larger population in breast cancer

By George W. Sledge Jr.

The plenary session at the ASCO 2022 annual meeting saw that rarest of things at a scientific conference: a standing ovation.

Clinical

In early results “unprecedented in rectal cancer,” 14/14 patients show clinical complete response to dostarlimab

By Alice Tracey

Lowy calls for expanding NCI’s clinical impact, including: (1) the number of drug candidates, (2) the clinical trials system, and (3) access to cancer care

By Alice Tracey

Free Obituary

Moffitt’s Robert Gillies, “father of radiomics,” dies at 69

By Kim Polacek

Free Obituary

Lucius Sinks, a giant in pediatric cancer, dies at 91
“We were able to come together at Roswell Park and help the kids.”

By Tim Wendel

Free Obituary

Lucius Sinks was the type of physician all of us would like to have

By Jerome Yates

Free Letter To The Editor

Tom Jordan: I wish to be known for Taxol, carboplatin, and camaraderie

By Thomas D. Jordon

Free In the Archives

How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission

By Deborah Doroshow and Alexandria Carolan

In Brief

Fadlo Khuri honored for decade as editor-in-chief of Cancer

AACR releases Cancer Disparities Progress Report 2022

Darrel Cohen named CMO of cell therapy at Athenex

Clinical Roundup

UNC study: Using telehealth to report symptoms improves well-being in advanced cancer

Parker Institute study: Biomarkers may predict better immunotherapy outcomes in mPDAC

N-803 immunotherapy may improve responses in BCG-unresponsive bladder cancer, advanced metastatic pancreatic cancer

Vectibix superior to bevacizumab in Japanese patients with wild-type RAS mCRC

Cedars-Sinai study shows racial and ethnic disparities in access to immunotherapy for advanced liver cancer

ACS study: Pandemic reduced breast, cervical, colorectal cancer screenings by millions in 2020

ACS study: Public perception of e-cigarettes vs. cigarettes harms changed sharply during EVALI epidemic and COVID-19 pandemic

Drugs & Targets

FDA grants Orphan Drug Designation to iadademstat in SCLC

Parker Institute for Cancer Immunotherapy, Resilience partner to develop cell and gene therapies

Dana-Farber, Gustave Roussy, L’Institut Servier sign oncology cooperation agreement

FDA campaign aims to prevent e-cigarette use among AI/AN youth

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 51 | Issue 35 - September 26, 2025

ASCO’s “rock concert” moments came 17 years apart—in 2005 and 2022

In early results “unprecedented in rectal cancer,” 14/14 patients show clinical complete response to dostarlimab

Lowy calls for expanding NCI’s clinical impact, including: (1) the number of drug candidates, (2) the clinical trials system, and (3) access to cancer care

Moffitt’s Robert Gillies, “father of radiomics,” dies at 69

Lucius Sinks, a giant in pediatric cancer, dies at 91
“We were able to come together at Roswell Park and help the kids.”

Lucius Sinks was the type of physician all of us would like to have

Tom Jordan: I wish to be known for Taxol, carboplatin, and camaraderie

How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission

In Brief

Fadlo Khuri honored for decade as editor-in-chief of Cancer

AACR releases Cancer Disparities Progress Report 2022

Darrel Cohen named CMO of cell therapy at Athenex

Clinical Roundup

UNC study: Using telehealth to report symptoms improves well-being in advanced cancer

Parker Institute study: Biomarkers may predict better immunotherapy outcomes in mPDAC

N-803 immunotherapy may improve responses in BCG-unresponsive bladder cancer, advanced metastatic pancreatic cancer

Vectibix superior to bevacizumab in Japanese patients with wild-type RAS mCRC

Cedars-Sinai study shows racial and ethnic disparities in access to immunotherapy for advanced liver cancer

ACS study: Pandemic reduced breast, cervical, colorectal cancer screenings by millions in 2020

ACS study: Public perception of e-cigarettes vs. cigarettes harms changed sharply during EVALI epidemic and COVID-19 pandemic

Drugs & Targets

FDA grants Orphan Drug Designation to iadademstat in SCLC

Parker Institute for Cancer Immunotherapy, Resilience partner to develop cell and gene therapies

Dana-Farber, Gustave Roussy, L’Institut Servier sign oncology cooperation agreement

FDA campaign aims to prevent e-cigarette use among AI/AN youth

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login